Search

Displaying results 3101 - 3110 of 10000 in total
  1. Drug

    Sapropterin

    go.drugbank.com/drugs/DB00360
    ApprovedInvestigational

    Sapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of

  2. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    [L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.

    Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
  3. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    [A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717] … [L44717] Anacaulase is indicated for eschar removal in patients with deep partial thickness and/or full-thickness thermal burns.

  4. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses. … The epitopes included in the vaccine were selected using Epitope Identification System (EIS) and each of them is predicted to be recognized in the majority of the prospective patient population.

  5. Drug

    Bezafibrate

    go.drugbank.com/drugs/DB01393
    ApprovedInvestigational

    Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.

  6. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    [A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory

  7. Drug

    Varlitinib

    go.drugbank.com/drugs/DB05944
    Investigational

    Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. … Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR.

  8. Drug

    Tenoxicam

    go.drugbank.com/drugs/DB00469
    ApprovedInvestigational

    Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.

  9. Drug

    Cycloserine

    go.drugbank.com/drugs/DB00260
    ApprovedInvestigational

    Antibiotic substance produced by Streptomyces garyphalus.

  10. Drug

    Azelaic acid

    go.drugbank.com/drugs/DB00548
    ApprovedInvestigational

    Azelaic acid is a saturated dicarboxylic acid found naturally in wheat, rye, and barley. … It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear.

    Synonyms: n-nonanedioic acid